|
|
|
2008 Small Cap Equity Conference
Presenter |
|
We would like to thank this company for
presenting at our 5th Annual Small Cap Equity Conference
held May 6th, 2008 at the Le
Parker Meridien New York City. If you missed the event, you can still
hear the presentations via our streaming audio archive.
Click
here Listen! |
|
Taglich's Company Profile
for: |
www.bioforcenano.com
|
BioForce Nanosciences Holdings, Inc. |
Symbol:
BFNH
Analyst:
Juan Noble
Taglich Rating:
Speculative Buy
Price Target:
$1.00
Time Horizon:
12 Months
Rating Established:
January 14, 2008
Price When Established:
$0.50
Most Recent Report:
January 14, 2008
Price When Issued:
$0.50
|
|
|
Most Recent Update |
|
Initial
Research Report (January 14, 2008) |
|
What's New |
|
New information will be posted soon... |
|
Company Description |
BioForce Nanosciences Holdings, Inc. (BFNH.OB), headquartered in Ames, IA, markets the Nano eNabler™, a benchtop molecular printer used to produce ultraminiaturized biolgical sensors, biolgical tests and other ultraminiaturized devices. The company produces proprietary consumables – surface patterning tools and silicon chips – to support the Nano eNabler, and is developing advanced diagnostics, standard and customized patterned surfaces, a high-throughput Nano eNabler system for use by biopharmaceutical firms and a Nano eNabler for use specifically in cellular biology research.
The Nano eNabler system can be used in the production of ultraminiaturized biological sensors, biomedical tests and other ultraminiaturized devices that could fuel growth of nanotechnology and overcome limitations of existing technologies aimed at microscale encoding. Researchers and scientists seeking to perform takes at the nanoscale are likely to turn increasingly to systems such as the Nano eNabler for their instrumentation needs.
Beyond commercialization of the Nano eNabler in the academic research community, the company aims to pursue development of proprietary diagnostics, therapeutics, self-diagnosis systems, and, ultimately, capabilities for personalized medicine. The company also aims to commercialize a high-throughput version of the Nano eNabler for production use in the biopharmaceutical industry. The ViriChip and nanodiagnostics, already in development, could be commercialized, respectively, by 2009 and 2010. Self-diagnosis and personalized medicine systems are longer-term development projects. |
|
Taglich Research Reports |
Initial report listed above....
All Research Reports are in Adobe Acrobat format.
(for the latest Adobe Acrobat reader click
here)
*The information and
statistical data contained herein have been obtained from
sources, which we believe to be reliable but in no way are
warranted by us as to accuracy or completeness. We do not
undertake to advise you as to changes in figures or our views.
This is not a solicitation of any order to buy or sell. Taglich
Brothers, Inc. is fully disclosed with its clearing firm,
Pershing, LLC, is not a market maker and does not sell to or buy
from customers on a principal basis. The above statements are
the opinion of Taglich Brothers, Inc. and are not a guarantee
that the target price for the stock will be met or that
predicted business results for the company will occur. There may
be instances when fundamental, technical and quantitative
opinions contained in the reports are not in concert. We, our
affiliates, any officer, director or stockholder or any member
of their families may from time to time purchase or sell any of
the above-mentioned or related securities. Analysts and members
of the Research Department are prohibited from buying or selling
securities issued by the companies that Taglich Brothers, Inc.
has a research relationship with, except if ownership of such
securities was prior to the start of such relationship, then an
Analyst or member of the Research Department may sell such
securities after obtaining expressed written permission from the
Director of Research. As of the date of this report, no officers
or employees of Taglich Brothers, Inc. owned any of the
company’s shares. All research issued by Taglich Brothers, Inc.
is based on public information. Taglich Brothers, Inc. does not
currently have an Investment Banking relationship with the
company mentioned and was not a manager or co-manager of any
offering for the company within the last three years. All
research issued by Taglich Brothers, Inc. is based on public
information. In November, 2007, the company paid a monetary fee
of US$24,000 for the creation and dissemination of research
reports for one year, and will, starting one year after the
publication of an initial research report, pay a monetary fee of
US$2,000 per month for the continued creation and dissemination
of research reports. For further information and Taglich
Brothers, Inc. ownership data please refer to each individual
report. |
|
Send this Page to a friend |
|
To send this page to a friend, just fill out the form below and press
the "send it" button!
|
|
|
Taglich Covered Companies |
AeroCentury Corp.
Anglo Swiss Resources, Inc.
Avensys Corporation
BioForce Nanosci. Holdings, Inc.
Caneum Inc.
Cardium Therapeutics, Inc.
China 3C Group
Command Security Corp.
CTI Industries Corp
Derma Sciences, Inc.
DRI Corporation
EnerLume Energy Mgt. Corp.
EP MedSystems, Inc.
Exeter Resource Corp.
GammaCan International, Inc.
Hartmarx Corporation
Helios & Matheson North America
INX, Inc.
Leading Brands, Inc.
Life Partners Holdings, Inc.
Lifeway Foods, Inc.
Littlefield Corporation
Manchester, Inc.
MFIC Corporation
Orchids Paper Products
Park City Group, Inc.
Pressure BioSciences, Inc.
QPC Lasers, Inc.
Radiant Logistics, Inc.
Reed's Inc.
Salon Media Group, Inc.
Simulations Plus, Inc.
TranSwitch Corporation
Triton Dist. Sys., Inc.
UFP Technologies, Inc.
US 1 Industries, Inc.
Wave Systems Corp.
Williams Controls, Inc.
|
|
